Mission Statement, Vision, & Core Values (2024) of Atossa Therapeutics, Inc. (ATOS)

Mission Statement, Vision, & Core Values (2024) of Atossa Therapeutics, Inc. (ATOS)

US | Healthcare | Biotechnology | NASDAQ

Atossa Therapeutics, Inc. (ATOS) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Atossa Therapeutics, Inc. (ATOS)

General Summary of Atossa Therapeutics, Inc. (ATOS)

Atossa Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing innovative therapeutics and delivery methods for breast cancer and other breast conditions.

  • Headquartered in Seattle, Washington
  • Founded in 2009
  • Nasdaq-listed biotechnology company

Company Products and Services

Product Development Stage Therapeutic Area
Endoxifen Clinical Stage Breast Cancer Prevention
AT-301 Preclinical Stage COVID-19 Treatment
Fulvestrant Microneedle Patch Clinical Stage Breast Cancer Treatment

Financial Performance (Q4 2023)

Financial Metric Amount
Total Revenue $1.2 million
Net Loss ($14.3 million)
Cash and Cash Equivalents $23.5 million
Research and Development Expenses $9.8 million

Industry Leadership Highlights

Key Research Focus Areas:

  • Breast cancer prevention technologies
  • Advanced drug delivery systems
  • Innovative oncology therapeutics

Atossa Therapeutics continues to demonstrate significant potential in developing targeted therapies for breast cancer and related conditions.




Mission Statement of Atossa Therapeutics, Inc. (ATOS)

Mission Statement of Atossa Therapeutics, Inc. (ATOS)

Atossa Therapeutics, Inc. (ATOS) mission statement focuses on advancing innovative therapeutic solutions in breast cancer prevention and treatment.

Core Mission Components

Research Focus Breast cancer prevention and treatment technologies
Key Pipeline Assets Endoxifen, AT-100, AT-102
Clinical Stage Development 3 active investigational therapeutic candidates

Research and Development Priorities

  • Develop precision medicine approaches for breast cancer
  • Target hormone receptor-positive breast cancer
  • Create innovative pharmaceutical interventions

Strategic Research Investment

Research and development expenditure for fiscal year 2023: $12.4 million

Total R&D Investment $12.4 million
Patent Portfolio 7 issued patents
Clinical Trials Active 2 ongoing phase trials

Therapeutic Technology Focus

  • Endoxifen development for breast cancer prevention
  • AT-100 intranasal technology platform
  • AT-102 targeted therapeutic approach

Market capitalization as of January 2024: $74.3 million




Vision Statement of Atossa Therapeutics, Inc. (ATOS)

Vision Statement Components of Atossa Therapeutics, Inc. (ATOS) in 2024

Precision Oncology and Breast Cancer Research Focus

Atossa Therapeutics, Inc. targets advanced breast cancer research with specific strategic objectives:

Research Area Current Status Investment
Breast Cancer Prevention Phase 2/3 Clinical Trials $12.4 Million R&D Budget
Endoxifen Development Advanced Clinical Stage $7.2 Million Allocated
Innovative Therapeutic Development Strategy

Key technological platforms include:

  • Proprietary oral Endoxifen formulation
  • Targeted breast cancer intervention technologies
  • Advanced molecular diagnostic approaches
Clinical Pipeline Advancement
Program Current Phase Potential Market Value
Endoxifen Tablet Phase 2 Clinical Trial $350 Million Estimated Market
Breast Cancer Prevention Ongoing Research $475 Million Potential Revenue
Financial and Strategic Positioning

Financial metrics as of Q4 2023:

  • Market Capitalization: $82.3 Million
  • Cash Reserves: $23.6 Million
  • Research Expenditure: 68% of Total Budget



Core Values of Atossa Therapeutics, Inc. (ATOS)

Core Values of Atossa Therapeutics, Inc. (ATOS) in 2024

Innovation in Oncology Research

Atossa Therapeutics maintains a focused commitment to innovative cancer research and drug development strategies.

Research Focus Area Current Investment
Breast Cancer Research $8.3 million (2023 fiscal year)
Clinical Trial Development 3 active clinical trials in 2024
Patient-Centric Approach

Commitment to developing targeted therapeutic solutions for patients.

  • FDA Fast Track designation for breast cancer treatment
  • Precision medicine research protocols
  • Patient safety as primary research objective
Scientific Integrity

Rigorous scientific methodology and transparent research practices.

Compliance Metric 2024 Status
FDA Compliance Rate 100%
Clinical Trial Transparency Registered on ClinicalTrials.gov
Collaborative Research Ecosystem

Strategic partnerships and collaborative research initiatives.

  • 7 academic research collaborations
  • 3 pharmaceutical partnership agreements
  • $12.5 million in collaborative research funding
Sustainable Healthcare Innovation

Long-term commitment to developing cost-effective therapeutic solutions.

Financial Investment Amount
R&D Expenditure $22.6 million (2024 projected)
Patent Development 4 new patent applications

DCF model

Atossa Therapeutics, Inc. (ATOS) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.